Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis

被引:10
作者
Buxhofer-Ausch, Veronika [2 ,3 ]
Gisslinger, Heinz [2 ]
Berg, Tiina [1 ]
Gisslinger, Bettina [2 ]
Kralovics, Robert [1 ,2 ]
机构
[1] Austrian Acad Sci, CeMM, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Haematol & Blood Coagulat, Vienna, Austria
[3] Donauspital, Dept Med 2, Vienna, Austria
关键词
MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA-VERA; JAK2; MPL515;
D O I
10.1111/j.1600-0609.2008.01183.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:161 / 163
页数:3
相关论文
共 10 条
[1]   The role of interferon-α in the treatment of idiopathic myelofibrosis [J].
Bachleitner-Hofmann, T ;
Gisslinger, H .
ANNALS OF HEMATOLOGY, 1999, 78 (12) :533-538
[2]   Molecular genetics and cytogenetics of myeloproliferative disorders [J].
Bench, AJ ;
Nacheva, EP ;
Champion, KM ;
Green, AR .
BAILLIERES CLINICAL HAEMATOLOGY, 1998, 11 (04) :819-848
[3]   Mechanisms of disease: The myeloproliferative disorders [J].
Campbell, Peter J. ;
Green, Anthony R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2452-2466
[4]   A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].
Kralovics, R ;
Passamonti, F ;
Buser, AS ;
Teo, S ;
Tiedt, R ;
Passweg, JR ;
Tichelli, A ;
Cazzola, M ;
Skoda, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790
[5]   Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders [J].
Kralovics, Robert ;
Teo, Soon-Siong ;
Li, Sai ;
Theocharides, Alexandre ;
Buser, Andreas S. ;
Tichelli, Andre ;
Skoda, Radek G. .
BLOOD, 2006, 108 (04) :1377-1380
[6]   Concurrent MPL515 and JAK2V617F mutations in myelofibrosis:: chronology of clonal emergence and changes in mutant allele burden over time [J].
Lasho, Terra L. ;
Pardanani, Animesh ;
McClure, Rebecca F. ;
Mesa, Ruben A. ;
Levine, Ross L. ;
Gilliland, D. Gary ;
Tefferi, Ayalew .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (05) :683-687
[7]   Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations [J].
Li, Sai ;
Kralovics, Robert ;
De Libero, Gennaro ;
Theocharides, Alexandre ;
Gisslinger, Heinz ;
Skoda, Radek C. .
BLOOD, 2008, 111 (07) :3863-3866
[8]   MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients [J].
Pardanani, Animesh D. ;
Levine, Ross L. ;
Lasho, Terra ;
Pikman, Yana ;
Mesa, Ruben A. ;
Wadleigh, Martha ;
Steensma, David P. ;
Elliott, Michelle A. ;
Wolanskyj, Alexandra R. ;
Hogan, William J. ;
McClure, Rebecca F. ;
Litzow, Mark R. ;
Gilliland, D. Gary ;
Tefferi, Ayalew .
BLOOD, 2006, 108 (10) :3472-3476
[9]   MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia [J].
Pikman, Yana ;
Lee, Benjamin H. ;
Mercher, Thomas ;
McDowell, Elizabeth ;
Ebert, Benjamin L. ;
Gozo, Maricel ;
Cuker, Adam ;
Wernig, Gerlinde ;
Moore, Sandra ;
Galinsky, Ilene ;
DeAngelo, Daniel J. ;
Clark, Jennifer J. ;
Lee, Stephanie J. ;
Golub, Todd R. ;
Wadleigh, Martha ;
Gilliland, D. Gary ;
Levine, Ross L. .
PLOS MEDICINE, 2006, 3 (07) :1140-1151
[10]   JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis [J].
Scott, Linda M. ;
Tong, Wei ;
Levine, Ross L. ;
Scott, Mike A. ;
Beer, Philip A. ;
Stratton, Michael R. ;
Futreal, P. Andrew ;
Erber, Wendy N. ;
McMullin, Mary Frances ;
Harrison, Claire N. ;
Warren, Alan J. ;
Gilliland, D. Gary ;
Lodish, Harvey F. ;
Green, Anthony R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (05) :459-468